Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
Baxter
Johnson and Johnson
Medtronic

Last Updated: August 19, 2022

Investigational Drug Information for Molidustat


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Molidustat?

Molidustat is an investigational drug.

There have been 10 clinical trials for Molidustat. The most recent clinical trial was a Phase 3 trial, which was initiated on February 22nd 2018.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Renal Insufficiency, and Anemia. The leading clinical trial sponsors are Bayer and [disabled in preview].

There are eighteen US patents protecting this investigational drug and three hundred and five international patents.

Recent Clinical Trials for Molidustat
TitleSponsorPhase
Maintenance Treatment of Renal Anemia in Dialysis SubjectsBayerPhase 3
A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis SubjectsBayerPhase 3
A Study of Molidustat for Correction of Renal Anemia in Dialysis SubjectsBayerPhase 3

See all Molidustat clinical trials

Clinical Trial Summary for Molidustat

Top disease conditions for Molidustat
Top clinical trial sponsors for Molidustat

See all Molidustat clinical trials

US Patents for Molidustat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Molidustat See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Molidustat See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Molidustat See Plans and Pricing Method for the preparation of triazole compounds BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) See Plans and Pricing
Molidustat See Plans and Pricing Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Molidustat

Drugname Country Document Number Estimated Expiration Related US Patent
Molidustat Australia AU2017261372 2036-05-05 See Plans and Pricing
Molidustat Canada CA3023278 2036-05-05 See Plans and Pricing
Molidustat China CN107847398 2036-05-05 See Plans and Pricing
Molidustat European Patent Office EP3452003 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
Baxter
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.